Top Markets
#1 Black Phoenix Black Phoenix +21,279.43%
#2 Nesa Nesa +680.24%
#3 Ontology Gas Ontology Gas +79.73%
#4 Kinesis Silver Kinesis Silver +54.00%
#5 Biconomy Biconomy +38.09%
#6 QuantixAI QuantixAI +23.11%
#7 EXOD EXOD +22.78%
#8 Magma Finance Magma Finance +18.80%
#9 SAFEcoin SAFEcoin +18.27%
#10 BNB Attestation Service BNB Attestation Service +18.17%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Camurus AB Camurus AB

Camurus AB

CAMX
Classificação em ações #4179
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Preço da ação
$67.97
Valor de mercado
$4.04B
Variação (1 dia)
-1.06%
Variação (1 ano)
-7.50%
País
SE
Negociar Camurus AB (CAMX)

Categoria

Healthcare
Histórico de preços das ações de Camurus AB (CAMX)
Preço de fecho mais alto: $69.18 em 2026-08-01

Preço de fecho mais baixo: $7.87 em 2015-12-01
Histórico de preços das ações da Camurus AB de 2015 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 0.49%
2025 26.88%
2024 4.43%
2023 92.92%
2022 53.39%
2021 -24.41%
2020 143.97%
2019 -13.20%
2018 -26.98%
2017 23.80%
2016 45.06%
2015 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.93 42.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 48.01%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $147.42 496.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $766.55 6.54%
CH